Data / Drug companies / Kenvue Brands LLC
Kenvue Brands LLC: 8 products in the FDA NDC directory, labeler code 16837
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Kenvue Brands LLC (labeler code 16837) lists 8 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 6 over the counter drugs, 2 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 11, 2024.
The request: Watch Kenvue Brands LLC (FDA labeler code 16837): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 16837
- Products in commercial distribution
- 8
- Packages
- 44
- Finished drugs by generic name
- 2
- Prescription products
- 0
- Over the counter products
- 6
- Flagged as original packager
- 6 of 6 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- October 1, 1995
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 6 | 75% |
| Drugs for further processing | 2 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 6 | 75% |
| Drugs for further processing | 2 | 25% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Famotidine | 3 | 138 |
| Famotidine, calcium carbonate, and magnesium hydroxide | 3 | 5 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, chewable | 5 | 62.5% |
| Tablet, film coated | 3 | 37.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Histamine-2 Receptor Antagonist | 6 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Maximum Strength PEPCID AC Icy Cool Mint | 16837-889 | Tablet, film coated | New drug applications (NDA) | March 11, 2024 |
| Famotidine, calcium carbonate, and magnesium hydroxide | 16837-839 | Tablet, chewable | Drugs for further processing | January 31, 2020 |
| Famotidine, calcium carbonate, and magnesium hydroxide | 16837-840 | Tablet, chewable | Drugs for further processing | May 1, 2019 |
| Pepcid Complete | 16837-891 | Tablet, chewable | New drug applications (NDA) | March 1, 2009 |
| Pepcid Complete | 16837-298 | Tablet, chewable | New drug applications (NDA) | March 1, 2009 |
| Pepcid Complete | 16837-246 | Tablet, chewable | New drug applications (NDA) | January 1, 2009 |
| PEPCID AC Maximum Strength | 16837-855 | Tablet, film coated | New drug applications (NDA) | September 1, 2003 |
| Pepcid AC Original Strength | 16837-872 | Tablet, film coated | New drug applications (NDA) | October 1, 1995 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.